{"title":"[给人注射[177Lu]Lu-PSMA-617后住院室内空气放射性的测量]。","authors":"Anri Inaki, Kenji Hirata, Hiroya Kambara, Satoshi Nomura, Toru Hattori, Makoto Hosono","doi":"10.18893/kakuigaku.oa.2201","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>[<sup>177</sup>Lu]Lu-PSMA-617 is a radioisotope used in nuclear medicine. It is necessary to take appropriate measures to limit its exposure and ensures its airborne concentrations do not exceed legally permitted levels. Therefore, the purpose of this study was to measure the airborne radioactivity concentration in the inpatient room after administering [<sup>177</sup>Lu]Lu-PSMA-617 to humans.</p><p><strong>Methods: </strong>Three males with advanced prostate-specific membrane antigen (PSMA)-positive metastatic castration resistant prostate cancer were intravenously administered [<sup>177</sup>Lu]Lu-PSMA-617 (7.4 GBq ± 10%) in an inpatient room, and the airborne radioactivity concentrations were measured at two locations in the room (in the center of the room and at the bedside) using a filter collection method.</p><p><strong>Results: </strong>After administration of [<sup>177</sup>Lu]Lu-PSMA-617, the airborne radioactivity concentrations measured were below the limit of detection (1.1 × 10<sup>-6</sup> Bq/cm<sup>3</sup> or 9.5 × 10<sup>-7</sup> Bq/cm<sup>3</sup>) in all three humans, and all concentrations were consistently below the standard value of 1/10,000 of 2 × 10<sup>-2</sup> Bq/cm<sup>3</sup>, the legal airborne concentration limit of <sup>177</sup>Lu.</p><p><strong>Conclusion: </strong>The results of this study confirmed that the airborne concentration of [<sup>177</sup>Lu]Lu-PSMA-617 after administration to humans was below the legally permitted level.</p>","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":" ","pages":"51-55"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Measurement of Airborne Radioactivity in the Inpatient Room after Administering [<sup>177</sup>Lu]Lu-PSMA-617 to Humans].\",\"authors\":\"Anri Inaki, Kenji Hirata, Hiroya Kambara, Satoshi Nomura, Toru Hattori, Makoto Hosono\",\"doi\":\"10.18893/kakuigaku.oa.2201\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>[<sup>177</sup>Lu]Lu-PSMA-617 is a radioisotope used in nuclear medicine. It is necessary to take appropriate measures to limit its exposure and ensures its airborne concentrations do not exceed legally permitted levels. Therefore, the purpose of this study was to measure the airborne radioactivity concentration in the inpatient room after administering [<sup>177</sup>Lu]Lu-PSMA-617 to humans.</p><p><strong>Methods: </strong>Three males with advanced prostate-specific membrane antigen (PSMA)-positive metastatic castration resistant prostate cancer were intravenously administered [<sup>177</sup>Lu]Lu-PSMA-617 (7.4 GBq ± 10%) in an inpatient room, and the airborne radioactivity concentrations were measured at two locations in the room (in the center of the room and at the bedside) using a filter collection method.</p><p><strong>Results: </strong>After administration of [<sup>177</sup>Lu]Lu-PSMA-617, the airborne radioactivity concentrations measured were below the limit of detection (1.1 × 10<sup>-6</sup> Bq/cm<sup>3</sup> or 9.5 × 10<sup>-7</sup> Bq/cm<sup>3</sup>) in all three humans, and all concentrations were consistently below the standard value of 1/10,000 of 2 × 10<sup>-2</sup> Bq/cm<sup>3</sup>, the legal airborne concentration limit of <sup>177</sup>Lu.</p><p><strong>Conclusion: </strong>The results of this study confirmed that the airborne concentration of [<sup>177</sup>Lu]Lu-PSMA-617 after administration to humans was below the legally permitted level.</p>\",\"PeriodicalId\":17738,\"journal\":{\"name\":\"Kaku igaku. The Japanese journal of nuclear medicine\",\"volume\":\" \",\"pages\":\"51-55\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kaku igaku. The Japanese journal of nuclear medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18893/kakuigaku.oa.2201\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kaku igaku. The Japanese journal of nuclear medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18893/kakuigaku.oa.2201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Measurement of Airborne Radioactivity in the Inpatient Room after Administering [177Lu]Lu-PSMA-617 to Humans].
Objective: [177Lu]Lu-PSMA-617 is a radioisotope used in nuclear medicine. It is necessary to take appropriate measures to limit its exposure and ensures its airborne concentrations do not exceed legally permitted levels. Therefore, the purpose of this study was to measure the airborne radioactivity concentration in the inpatient room after administering [177Lu]Lu-PSMA-617 to humans.
Methods: Three males with advanced prostate-specific membrane antigen (PSMA)-positive metastatic castration resistant prostate cancer were intravenously administered [177Lu]Lu-PSMA-617 (7.4 GBq ± 10%) in an inpatient room, and the airborne radioactivity concentrations were measured at two locations in the room (in the center of the room and at the bedside) using a filter collection method.
Results: After administration of [177Lu]Lu-PSMA-617, the airborne radioactivity concentrations measured were below the limit of detection (1.1 × 10-6 Bq/cm3 or 9.5 × 10-7 Bq/cm3) in all three humans, and all concentrations were consistently below the standard value of 1/10,000 of 2 × 10-2 Bq/cm3, the legal airborne concentration limit of 177Lu.
Conclusion: The results of this study confirmed that the airborne concentration of [177Lu]Lu-PSMA-617 after administration to humans was below the legally permitted level.
期刊介绍：
The main scope of JSNM is the appropriate development of the application of radioactive substances and stable nuclides in medicine. Towards this scope, JSNM promotes the exchange of idea and information, and researches in nuclear medicine. JSNM are interested in the international collaboration for the development of nuclear medicine. Through the activities, JSNM contributes to the medicine, as well as humanity, not only in Japan but also in any countries over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
